Business & Finance
Business and Finance
Business and Finance
Wed, November 10, 2010
Tue, November 9, 2010 InVivo Therapeutics CEO to Address 5th Annual Working 2 Walk Science & Advocacy Symposium
CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--InVivo Therapeutics (OTCBB: NVIV), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that Frank Reynolds, CEO of InVivo, will address the 5th Annual Working 2 Walk Science & Advocacy Symposium taking place November 11 a" 13, 2010 in Phoenix, Arizona. Mr. Reynoldsa™ remarks, titled "Changing the Face of Neuroscience: Are Stem Cells Really Required to Heal a Spinal Cord Injury?a will be given at 9:10am ET on Friday, November 12.
"Changing the Face of Neuroscience: Are Stem Cells Really Required to Heal a Spinal Cord Injury?"
aThe annual Working 2 Walk symposium is a key gathering of the paralysis community and one at which I am honored to be a speaker,a said Mr. Reynolds. aAmong the groundbreaking technologies under development at InVivo is a treatment which combines human neural stem cells with our novel biocompatible polymer scaffolding device.a Mr. Reynolds added that this treatment approach, designed to augment neural repair potential, will be featured in his discussions on the use and value of stem cells in the treatment of SCI.
The Annual Working 2 Walk Science & Advocacy Symposium brings together key players in the paralysis community in an effort to bring curative therapies to reality. Research scientists, practitioners and community members meet to exchange information and develop strategies for accelerating the cure. For more information, please visit: [ http://www.working2walk.org ].
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who is affiliated with Massachusetts General Hospital in Boston.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Companya™s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
